Cargando…
Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study
BACKGROUND: Fingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long-term effects on the immunological profile are not fully understood. OBJECTIVE: Investigate fingolimod's temporal effects on immune cell subsets, and safety outcomes. METHODS: In FLUENT, a 12-m...
Autores principales: | Mao-Draayer, Yang, Cohen, Jeffrey A, Bar-Or, Amit, Han, May H, Singer, Barry, Williams, Ian M, Meng, Xiangyi, Elam, Chelsea, Weiss, Jamie L, Cox, Gina Mavrikis, Ziehn, Marina, Cree, Bruce AC |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346260/ https://www.ncbi.nlm.nih.gov/pubmed/35936922 http://dx.doi.org/10.1177/20552173221115023 |
Ejemplares similares
-
The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod
por: Cohen, Jeffrey A, et al.
Publicado: (2019) -
Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS
por: Fox, Edward J., et al.
Publicado: (2019) -
Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis
por: Ghadiri, Mahtab, et al.
Publicado: (2020) -
Fluent Python
por: Ramalho, Luciano
Publicado: (2021) -
Fluent C#
por: Riordan, Rebecca
Publicado: (2011)